Arcturus Therapeutics

Arcturus Therapeutics Holdings, Inc. develops pharmaceuticals. It is a clinical-stage mRNA medicines and vaccines company, which focuses on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. The firm's products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Arcturus Therapeutics reports robust earnings and advances in mRNA pipeline

Arcturus Therapeutics delivered strong financial results and showcased progress across key strategic areas
The company's collaborations, advancements in RNA technology, and clinical trial milestones position it for future success
While facing competition and challenges, Arcturus has opportunities to leverage its strengths and drive growth in the mRNA space

Arcturus reports strong Q1 earnings, advances COVID vaccine development

Arcturus Therapeutics demonstrated robust financial performance, progress in COVID-19 vaccine development, and advancements in mRNA therapeutics.
While facing challenges in drug safety and regulatory approvals, the company is well-positioned to capitalize on opportunities for expansion and innovation.
Strategic collaborations and a strong cash position enhance Arcturus' competitive edge and potential for sustained growth in the biopharmaceutical sector.

Arcturus Therapeutics reports Q2 results, advances key programs with CSL

Arcturus Therapeutics showcased financial resilience with a strong cash position and promising program advancements in Q2 2023.
While facing challenges such as high operating expenses and uncertainties in clinical trials, the company is leveraging opportunities for market expansion and program advancement.
Collaboration with CSL and progress on key programs like ARCT-154 and ARCT-810 position Arcturus for continued growth and innovation in the biopharmaceutical space.
Investors can look forward to data releases, program updates, and potential market expansions as Arcturus navigates financial challenges and capitalizes on growth opportunities.

Arcturus Therapeutics excels in Q3 with promising pipeline advancements

Arcturus Therapeutics demonstrated strong financial performance, operational efficiency, and clinical progress in key pipeline candidates, positioning the company for future growth and success.
The company's technological strengths, diverse pipeline, and strategic partnerships underscore its innovation and commitment to addressing unmet medical needs, enhancing market competitiveness.
While facing challenges in regulatory approvals and study outcomes, Arcturus has opportunities to expand its product portfolio, leverage mRNA technology advantages, and drive market growth through strategic planning.
Overall, Arcturus' Q3 earnings call highlights a balanced outlook of financial stability, clinical advancements, and strategic opportunities, signaling a positive trajectory for the company's future.

Arcturus Therapeutics reports mixed financials but strong vaccine pipeline

Arcturus Therapeutics faces financial challenges with expenses exceeding revenues, but maintains a stable cash runway and strong pipeline of vaccine programs
The company's focus on vaccine development for various diseases and mRNA therapeutics showcases promising strengths and diversification in its product offerings
Opportunities in the Japanese market, upcoming Phase II study results, and operational advancements present avenues for growth and value creation for Arcturus

Arcturus reports Q1 results, eyes growth through clinical progress

Arcturus Therapeutics reported mixed financial results in Q1 2024 but remains well-positioned with strong cash reserves and ongoing clinical advancements.
Challenges include managing expenses, revenue variability, and timing uncertainties in future guidance tied to Kostaive revenues.
However, opportunities lie in positive trial outcomes, potential milestone payments, and strategic alignment with global health initiatives.
Overall, Arcturus shows promise in its financial stability, clinical progress, and strategic positioning for future growth and innovation.

Arcturus Therapeutics excels in Q2 2024, poised for mRNA innovation

Arcturus Therapeutics demonstrated strong financial performance and progress in key programs, supported by a solid cash position and strategic collaborations.
While facing challenges such as cost management and regulatory complexities, the company is well-positioned to leverage opportunities in mRNA therapeutics and vaccine development.
Overall, Arcturus shows promise in advancing its pipeline and capturing growth opportunities in the evolving biopharmaceutical landscape.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

On ARCT's third-quarter 2024 earnings call, investors' focus is likely to be on the upcoming launch of its COVID-19 vaccine, Kostaive and other pipeline updates.

Arcturus Gears Up to Report Q3 Earnings: Here's What to Expect

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA vaccines and medicines company focused on the development of infectious disease vaccines and addressing unmet medical needs within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended September 30, 2024 after the market close on Thursday, November 7 and will also host a conference call and webcast a.

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024

Arcturus Therapeutics (ARCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Arcturus Therapeutics (ARCT) Upgraded to Buy: What Does It Mean for the Stock?

Arcturus stock gains as the company reports that its sa-mRNA COVID-19 vaccine, ARCT-154, shows superior efficacy compared with treatment with Comirnaty.

ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty

CSL Ltd

WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and self-amplifying messenger RNA (sa-mRNA) pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced the results of a head-to-head study demonstrating that self-amplifying (sa-mRNA) COVID-19 vaccine maintained superior immunogenicity compared to the conventional mRNA vaccine Comirnaty® for up to one year against Wuhan-Hu-1, Omicron BA.4-5 and certain other variants, and at one-sixth the dose.

Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination

Here, we are discussing some reasons why investing in ARCT stock now may turn out to be a prudent move.

Here's Why Investors Should Invest in Arcturus Stock Now

AngioDynamics

First Mid-Illinois Bancshares

M/I Homes

Pampa Energia

ARCT, MHO, FMBH, PAM and ANGO have been added to the Zacks Rank #1 (Strong Buy) List on September 13, 2024.

New Strong Buy Stocks for September 13th

Approval underscores CSL and Arcturus Therapeutics' commitment to delivering disruptive technologies to combat COVID-19 and other respiratory viral diseases to protect public health KOSTAIVE®, the world's first self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, was approved for adults 18 years of age and older in November 2023 The updated sa-mRNA COVID-19 vaccine is tailored to protect against the JN.1 lineage of Omicron subvariants Meiji Seika Pharma, CSL's exclusive partner in Japan, will begin vaccine distribution in time for the October COVID-19 vaccination campaign  CSL and Arcturus Therapeutics' partnership delivers on the promise to advance innovative vaccine technology for viral respiratory diseases KING OF PRUSSIA, Pa. and SAN DIEGO , Sept.

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and addressing unmet medical needs within liver and respiratory rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a “Study May Proceed” notification for the Company's Investigational New Drug (IND) application, ARCT-032, to treat cystic fibrosis (CF).

Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis

The average of price targets set by Wall Street analysts indicates a potential upside of 216.4% in Arcturus Therapeutics (ARCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Arcturus Therapeutics (ARCT) Have the Potential to Rally 216.35% as Wall Street Analysts Expect?

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and addressing unmet medical needs within liver and respiratory rare diseases, today announced that the Company will participate in the following investor and scientific conferences: Wells Fargo 2024 Healthcare Conference (Fireside Chat) Wednesday, September 4, 2024 (3:00 p.m. ET) RNA Leaders.

Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences

Arcturus Therapeutics (ARCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Arcturus Therapeutics (ARCT) a New Strong Buy Stock

First Community

Roche Holding AG

Southside Bancshares

RHHBY, SBSI, FCCO, APELY and ARCT have been added to the Zacks Rank #1 (Strong Buy) List on August 23, 2024.

New Strong Buy Stocks for August 23rd

Arcturus is close to launching the Kostaive COVID-19 vaccine in Japan, with ongoing work on variant protection and influenza vaccine. The company has been able to consistently derive research revenues, maintaining liquidity and avoiding debt, with potential for significant revenue from vaccine orders. Valuation suggests Arcturus may be undervalued compared to peers, with a revised model showing potential for significant revenue growth by 2026.

High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q2 2024 Earnings Call Transcript August 5, 2024 4:30 PM ET Company Participants Neda Safarzadeh - VP, Head of IR, Public Relations and Marketing Joe Payne - President and CEO Andy Sassine - CFO Conference Call Participants Joohwan Kim - Canaccord Genuity Yasmeen Rahimi - Piper Sandler Evan Wang - Guggenheim Securities Myles Minter - William Blair Yanan Zhu - Wells Fargo Yigal Nochomovitz - Citigroup Samantha Schaeffer - Cantor Fitzgerald Ed Arce - H.C. Wainwright Yale Jen - Laidlaw & Company Operator Greetings and welcome to Arcturus Therapeutics' Second Quarter 2024 Earnings Call.

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2024 Earnings Call Transcript

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $1.85. This compares to loss of $1.98 per share a year ago.

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and addressing unmet medical needs within liver and respiratory rare diseases, today announced its financial results for the second quarter ended June 30, 2024, and provided corporate updates. “We are pleased to remain on track for our first commercial product launch of Kostaive® in Japan lat.

Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced that the Company will present at Canaccord Genuity 44th Annual Growth Conference in Boston, on Tuesday, August 13, 2024, at 9:30 am Eastern Time. A webcast and replay of the presentation wil.

Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2024 after the market close on Monday, August 5 and will also host a conference call and webcast at 4:30 pm Eastern.

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today is providing mid-year updates for ARCT-810, an investigational mRNA therapeutic to treat ornithine transcarbamylase (OTC) deficiency, and ARCT-032, an investigational inhaled mRNA therapeutic to treat.

Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced the appointment of a new independent director, Moncef Slaoui, Ph.D., to the Company's Board of Directors. “Dr. Moncef Slaoui brings extraordinary strategic expertise in pharmaceutical produc.

Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors

Arcturus is a top pick in the biotech sector with a strong stock market performance. The company generates revenue from research and development partnerships, which helps conserve cash. The launch of the Kostaive vaccine and other programs are expected to drive revenue growth in the short and long term.

Arcturus: A Hidden Gem In The Biotech Sector

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today presented Phase 1 results in healthy volunteers and Phase 1b interim data in people with CF for ARCT-032, an inhaled investigational mRNA therapeutic, at the 47th European Cystic Fibrosis Conference i.

Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced Arcturus will be presenting Phase 1 results in healthy volunteers and new Phase 1b interim data in CF patients for ARCT-032, an inhaled investigational mRNA therapeutic t.

Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program

KING OF PRUSSIA, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announce Nature Communications has published results from an integrated phase 1/2/3a/3b study evaluating the safety, immunogenicity, and efficacy of ARCT-154, a novel self-amplifying (sa-mRNA) COVID-19 vaccine and the world's first approved sa-mRNA COVID-19 vaccine. The results demonstrate that two 5 μg doses of ARCT-154, sa-mRNA vaccine, were.

News for Arcturus Therapeutics Stock (ARCT)